Sertralina w pytaniach i odpowiedziach Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2022
Słowa kluczowe:
selektywne inhibitory wychwytu zwrotnego serotoniny, sertralina, zaburzenia depresyjne, wiek podeszły, choroby somatyczne, działania niepożądane
##plugins.themes.bootstrap3.article.main##
Abstrakt
Sertralina to lek przeciwdepresyjny z grupy selektywnych inhibitorów wychwytu zwrotnego serotoniny. W stosunku do innych substancji z tej grupy odznacza się dodatkową zdolnością do blokady wychwytu zwrotnego dopaminy do wiązania z receptorami σ1. Nie ma zaś działania antycholinergicznego lub α1-adrenolitycznego czy histaminolitycznego. Z tego powodu odznacza się bardzo korzystnym profilem tolerancji i należy do wąskiej grupy leków przeciwdepresyjnych o szczególnie korzystnym, dobrze udokumentowanym profilu bezpieczeństwa i możliwości zastosowania u pacjentów z wieloma różnymi współistniejącymi schorzeniami somatycznymi oraz u osób starszych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Siwek, M. (2022). Sertralina w pytaniach i odpowiedziach . Medycyna Faktów , 15(3(56), 307-314. https://doi.org/10.24292/01.MF.0322.6
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Lalji HM, McGrogan A, Bailey SJ. An analysis of antidepressant prescribing trends in England 2015 2019. J Affect Disord Rep. 2021; 6: 100205. http://doi.org/10.1016/j.jadr.2021.100205.
2. Bogowicz P, Curtis HJ, Walker AJ et al. Trends and variation in antidepressant prescribing in English primary care: a retrospective longitudinal study. BJGP Open. 2021; 5(4): BJGPO.2021.0020. http://doi.org/10.3399/BJGPO.2021.0020.
3. Siwek M. Dekalog leczenia depresji. Item Publishing, Warszawa 2021.
4. Stahl SM. Poradnik lekarza praktyka. Vol. 7. Via Medica, Gdańsk 2021.
5. Siwek M. Anhedonia w zaburzeniach depresyjnych. Psychiatr Psychol Klin. 2017; 17(3): 216-24. http://doi.org/10.15557/PiPK.2017.0026.
6. Rosenblat JD, Kakar R, McIntyre RS. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Int J Neuropsychopharmacol. 2015; 19(2): pyv082. http://doi.org/10.1093/ijnp/pyv082.
7. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66.
8. Cipriani A, La Ferla T, Furukawa TA et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010; (4): CD006117.
9. Charakterystyka produktu leczniczego: sertralina.
10. Slee A, Nazareth I, Bondaronek P et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis Lancet. 2019; 393(10173): 768-77.
11. Leombruni P, Pierò A, Lavagnino L et al. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1599-605.
12. Sloan DM, Mizes JS, Helbok C et al. Efficacy of sertraline for bulimia nervosa. Int J Eat Disord. 2004; 36(1): 48-54.
13. O’Reardon JP, Allison KC, Martino NS et al. A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry. 2006; 163(5): 893-8. http://doi.org/10.1176/ajp.2006.163.5.893.
14. Andrade Ch. Premenstrual dysphoric disorder: General overview, treatment strategies, and focus on sertraline for symptom-onset dosing. Indian J Psychiatry. 2016; 58(3): 329-31. http://doi.org/10.4103/0019-5545.192014.
15. Furukawa TA, Cipriani A, Cowen PJ et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019; 6(7): 601-9.
16. Jakubovski E, Johnson JA, Nasir M et al. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depress Anxiety. 2019; 36(3): 198-212.
17. Bloch MH, McGuire J, Landeros-Weisenberger A et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010; 15(8): 850-5.
18. Tedeschini E, Levkovitz Y, Iovieno N et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebocontrolled randomized trials. J Clin Psychiatry. 2011; 72(12): 1660-8. http://doi.org/10.4088/JCP.10r06531.
19. Thorlund K, Druyts E, Wu P et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015; 63(5): 1002-09.
20. Krause M, Gutsmiedl K, Bighelli I et al. Efficacy and tolerability of pharmacological and non pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-analysis. Eur Neuropsychopharmacol. 2019; 29(9): 1003-22.
21. Tham A, Jonsson U, Andersson G et al. Efficacy and tolerability of antidepressants in people aged 65 years or older with major depressive disorder – a systematic review and a meta-analysis. J Affect Disord. 2016; 205: 1-12.
22. Hsu T-W, Stubbs B, Liang Ch et al. Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis. Ageing Res Rev. 2021; 69: 101362. http://doi.org/10.1016/j.arr.2021.101362.
23. He Y, Li H, Huang J et al. Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis. J Psychopharmacol. 2021; 35(8): 901-9. http://doi.org/10.1177/02698811211030181.
24. Wishart DS, Feunang YD, Guo AC et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017. http://doi.org/10.1093/nar/gkx1037.
25. Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017; 102(1): 37-44. http://doi.org/10.1002/cpt.597.
26. Bazire S. Psychotropic drug directory.
27. a href=" http://doi.org/10.1001/jama.288.6.701"> Glassman AH, O’Connor ChM, Califf RM et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002; 288(6): 701-9. http://doi.org/10.1001/jama.288.6.701.
28. O’Connor CM, Jiang W, Kuchibhatla M et al.; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010; 56(9): 692-9.
29. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003; 108(1): 32-6. http://doi.org/10.1161/01.CIR.0000079172.43229.CD.
30. Woroń J, Siwek M, Gorostowicz A. Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders. Psychiatr Pol. 2019; 53(5): 977-95. http://doi.org/10.12740/PP/OnlineFirst/96286.
31. Lustman PJ, Clouse RE, Nix BD et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo- controlled trial. Arch Gen Psychiatry. 2006; 63(5): 521-9. http://doi.org/10.1001/archpsyc.63.5.521.
32. Petrak F, Herpertz S, Albus C et al. Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study: A Randomized Controlled Multicenter Trial. Diabetes Care. 2015; 38(5): 767-75. http://doi.org/10.2337/dc14-1599.
33. Padmapriya C, Pushkarapriya S, Shanmugapriya N et al. Effect of sertraline in patients with newly diagnosed depression and type 2 diabetes mellitus or hypertension: An observational study from south India. Diabetes Metab Syndr. 2020; 14(5): 1065-8. http://doi.org/1016/j.dsx.2020.06.059.
34. Uguz F, Sahingoz M, Gungor B et al. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry. 2015; 37(1): 46-8. http://doi.org/10.1016/j.genhosppsych.2014.10.011.
35. Fava M, Judge R, Hoog SL et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000; 61(11): 863-7. http://doi.org/10.4088/jcp.v61n1109.
36. Rachdi Ch, Damak R, Romdhane FF et al. Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients. Prim Care Diabetes. 2019; 13(1): 57-62. http://doi.org/10.1016/j.pcd.2018.09.003.
37. Categorization Of The Likelihood Of Drug Induced Liver Injury. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.-now.
38. Chen HY, Lin CL, Lai SW et al. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry. 2016; 77(6): e692-e696.
39. Erie JC, Brue SM, Chamberlain AM et al. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. Am J Ophthalmol. 2014; 158(1): 192-7.
40. Fu Y, Dai Q, Zhu L et al. Antidepressants use and risk of cataract development: a systematic review and meta-analysis. BMC Ophthalmol. 2018; 18(1): 31.
41. Steinert T, Fröscher W. Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review. Pharmacopsychiatry. 2018; 51(4): 121-35. http://doi.org/10.1055/s-0043-117962.
42. https://www.halesmeds.com/ (access: 22.07.2022).
2. Bogowicz P, Curtis HJ, Walker AJ et al. Trends and variation in antidepressant prescribing in English primary care: a retrospective longitudinal study. BJGP Open. 2021; 5(4): BJGPO.2021.0020. http://doi.org/10.3399/BJGPO.2021.0020.
3. Siwek M. Dekalog leczenia depresji. Item Publishing, Warszawa 2021.
4. Stahl SM. Poradnik lekarza praktyka. Vol. 7. Via Medica, Gdańsk 2021.
5. Siwek M. Anhedonia w zaburzeniach depresyjnych. Psychiatr Psychol Klin. 2017; 17(3): 216-24. http://doi.org/10.15557/PiPK.2017.0026.
6. Rosenblat JD, Kakar R, McIntyre RS. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Int J Neuropsychopharmacol. 2015; 19(2): pyv082. http://doi.org/10.1093/ijnp/pyv082.
7. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128): 1357-66.
8. Cipriani A, La Ferla T, Furukawa TA et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010; (4): CD006117.
9. Charakterystyka produktu leczniczego: sertralina.
10. Slee A, Nazareth I, Bondaronek P et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis Lancet. 2019; 393(10173): 768-77.
11. Leombruni P, Pierò A, Lavagnino L et al. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1599-605.
12. Sloan DM, Mizes JS, Helbok C et al. Efficacy of sertraline for bulimia nervosa. Int J Eat Disord. 2004; 36(1): 48-54.
13. O’Reardon JP, Allison KC, Martino NS et al. A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry. 2006; 163(5): 893-8. http://doi.org/10.1176/ajp.2006.163.5.893.
14. Andrade Ch. Premenstrual dysphoric disorder: General overview, treatment strategies, and focus on sertraline for symptom-onset dosing. Indian J Psychiatry. 2016; 58(3): 329-31. http://doi.org/10.4103/0019-5545.192014.
15. Furukawa TA, Cipriani A, Cowen PJ et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019; 6(7): 601-9.
16. Jakubovski E, Johnson JA, Nasir M et al. Systematic review and meta-analysis: Dose-response curve of SSRIs and SNRIs in anxiety disorders. Depress Anxiety. 2019; 36(3): 198-212.
17. Bloch MH, McGuire J, Landeros-Weisenberger A et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010; 15(8): 850-5.
18. Tedeschini E, Levkovitz Y, Iovieno N et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebocontrolled randomized trials. J Clin Psychiatry. 2011; 72(12): 1660-8. http://doi.org/10.4088/JCP.10r06531.
19. Thorlund K, Druyts E, Wu P et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015; 63(5): 1002-09.
20. Krause M, Gutsmiedl K, Bighelli I et al. Efficacy and tolerability of pharmacological and non pharmacological interventions in older patients with major depressive disorder: a systematic review, pairwise and network meta-analysis. Eur Neuropsychopharmacol. 2019; 29(9): 1003-22.
21. Tham A, Jonsson U, Andersson G et al. Efficacy and tolerability of antidepressants in people aged 65 years or older with major depressive disorder – a systematic review and a meta-analysis. J Affect Disord. 2016; 205: 1-12.
22. Hsu T-W, Stubbs B, Liang Ch et al. Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis. Ageing Res Rev. 2021; 69: 101362. http://doi.org/10.1016/j.arr.2021.101362.
23. He Y, Li H, Huang J et al. Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis. J Psychopharmacol. 2021; 35(8): 901-9. http://doi.org/10.1177/02698811211030181.
24. Wishart DS, Feunang YD, Guo AC et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017. http://doi.org/10.1093/nar/gkx1037.
25. Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017; 102(1): 37-44. http://doi.org/10.1002/cpt.597.
26. Bazire S. Psychotropic drug directory.
27. a href=" http://doi.org/10.1001/jama.288.6.701"> Glassman AH, O’Connor ChM, Califf RM et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002; 288(6): 701-9. http://doi.org/10.1001/jama.288.6.701.
28. O’Connor CM, Jiang W, Kuchibhatla M et al.; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010; 56(9): 692-9.
29. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003; 108(1): 32-6. http://doi.org/10.1161/01.CIR.0000079172.43229.CD.
30. Woroń J, Siwek M, Gorostowicz A. Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders. Psychiatr Pol. 2019; 53(5): 977-95. http://doi.org/10.12740/PP/OnlineFirst/96286.
31. Lustman PJ, Clouse RE, Nix BD et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo- controlled trial. Arch Gen Psychiatry. 2006; 63(5): 521-9. http://doi.org/10.1001/archpsyc.63.5.521.
32. Petrak F, Herpertz S, Albus C et al. Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study: A Randomized Controlled Multicenter Trial. Diabetes Care. 2015; 38(5): 767-75. http://doi.org/10.2337/dc14-1599.
33. Padmapriya C, Pushkarapriya S, Shanmugapriya N et al. Effect of sertraline in patients with newly diagnosed depression and type 2 diabetes mellitus or hypertension: An observational study from south India. Diabetes Metab Syndr. 2020; 14(5): 1065-8. http://doi.org/1016/j.dsx.2020.06.059.
34. Uguz F, Sahingoz M, Gungor B et al. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry. 2015; 37(1): 46-8. http://doi.org/10.1016/j.genhosppsych.2014.10.011.
35. Fava M, Judge R, Hoog SL et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000; 61(11): 863-7. http://doi.org/10.4088/jcp.v61n1109.
36. Rachdi Ch, Damak R, Romdhane FF et al. Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients. Prim Care Diabetes. 2019; 13(1): 57-62. http://doi.org/10.1016/j.pcd.2018.09.003.
37. Categorization Of The Likelihood Of Drug Induced Liver Injury. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.-now.
38. Chen HY, Lin CL, Lai SW et al. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry. 2016; 77(6): e692-e696.
39. Erie JC, Brue SM, Chamberlain AM et al. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. Am J Ophthalmol. 2014; 158(1): 192-7.
40. Fu Y, Dai Q, Zhu L et al. Antidepressants use and risk of cataract development: a systematic review and meta-analysis. BMC Ophthalmol. 2018; 18(1): 31.
41. Steinert T, Fröscher W. Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review. Pharmacopsychiatry. 2018; 51(4): 121-35. http://doi.org/10.1055/s-0043-117962.
42. https://www.halesmeds.com/ (access: 22.07.2022).